AOX1 and fatty liver disease: On the contrary, following TRF intervention, the expression of hepatic AOX1 was restored to normal levels, accompanied by a decline in circulating levels of N-Me-6-PY and N-Me-4-PY, ultimately ameliorating hepatic steatosis.